KLRK1 and plasma cell myeloma: In conclusion, this study demonstrates that the combination of SMI‐16a and ABT888 enhances NK cell‐mediated tumor killing through the NKG2D/MICA signaling axis, promoting DNA damage and resulting in a stronger antitumor response against multiple myeloma.